Related Experiment Video

Updated: Jun 12, 2026

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha

Iris Eke1, Ulrike Koch, Stephanie Hehlgans

  • 1OncoRay - Center for Radiation Research in Oncology, Medical Faculty Carl Gustav Carus, Dresden University of Technology, 01307 Dresden, Germany.

The Journal of Clinical Investigation
|June 10, 2010
PubMed

Insights

Tumor cells resist radiation therapy partly due to the protein PINCH1 (particularly interesting new cysteine-histidine-rich 1). PINCH1 enhances survival by inhibiting PP1alpha, increasing Akt1 activity, and promoting radioresistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tumor cell resistance to radiation and chemotherapy is a significant challenge in cancer treatment.
  • Integrin-mediated adhesion to the extracellular matrix (ECM) contributes to this resistance.
  • The adapter protein PINCH1 (particularly interesting new cysteine-histidine-rich 1) is involved in cell survival at integrin adhesion sites, but its mechanisms are unclear.

Purpose of the Study:

  • To investigate the role of PINCH1 in tumor cell survival and resistance to ionizing radiation.
  • To elucidate the molecular mechanisms by which PINCH1 confers radioresistance.

Main Methods:

  • Quantitative analysis of PINCH1 expression in human tumors versus normal tissues.
  • In vitro and in vivo experiments assessing cell survival after ionizing radiation treatment.
  • Biochemical assays to determine the interaction between PINCH1, PP1alpha, and Akt1.

Main Results:

  • PINCH1 is upregulated in diverse human tumors compared to normal tissues.
  • PINCH1 overexpression enhances tumor cell survival following ionizing radiation exposure, both in vitro and in vivo.
  • PINCH1 directly binds to and inhibits protein phosphatase 1alpha (PP1alpha), leading to sustained Akt1 phosphorylation and activity, thus promoting radioresistance.

Conclusions:

  • PINCH1 plays a crucial role in promoting tumor cell survival and radioresistance.
  • Targeting PINCH1, a downstream signaling molecule of focal adhesions, may offer novel therapeutic strategies to overcome resistance to radio- and chemotherapy.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.